Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin

Lipids in Health and Disease

Research

Philippe Brudi¹  Amy O Johnson-Levonas¹  Qian Dong¹  Arvind Shah¹  Michel Farnier² 

[1] Merck, Sharp & Dohme Corp., Whitehouse Station, New Jersey, USA;Point Medical, 21000, Dijon, France;

关键词: high-density lipoprotein cholesterol;    fibrates;    dyslipidemia;    ezetimibe;    simvastatin;   

DOI  :  10.1186/1476-511X-10-212

 received in 2011-10-24, accepted in 2011-11-16,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundFibrates have been reported to cause paradoxical decreases in HDL-C in certain patients.Design and methodsThis post-hoc analysis explored the frequency/magnitude of HDL-C reductions in a pooled database of mixed dyslipidemic patients (LDL-C:3.4-5.7 mmol/L;TG:1.7-5.7 mmol/L) receiving placebo (PBO), fenofibrate (FENO), ezetimibe plus FENO (EZE+FENO), or EZE/simvastatin plus FENO (EZE/SIMVA+FENO) for 12 weeks.ResultsPBO-treated patients had the highest incidence of HDL-C reductions from baseline (45%) compared with patients taking FENO (14%), EZE+FENO (9%), or EZE/SIMVA+FENO (9%). Reductions <30% reflected natural variability since the largest reduction in HDL-C approached 30% in the PBO group. Only 3 patients exhibited HDL-C reductions ≥30% (i.e., 2 patients in the FENO group and 1 in the EZE+FENO group). There were no differences in demographic/biochemical characteristics between patients with and without HDL-C reductions.ConclusionsThe incidence of paradoxical HDL-C reductions was low in mixed dyslipidemic patients receiving FENO alone or combined with EZE or EZE/SIMVA.Trial registrationsClinicaltrials.gov: NCT00092560 and NCT00092573

【 授权许可】

CC BY   
© Farnier et al; licensee BioMed Central Ltd. 2011